Nature Communications (Nov 2021)
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury
- Tomokazu Yamaguchi,
- Midori Hoshizaki,
- Takafumi Minato,
- Satoru Nirasawa,
- Masamitsu N. Asaka,
- Mayumi Niiyama,
- Masaki Imai,
- Akihiko Uda,
- Jasper Fuk-Woo Chan,
- Saori Takahashi,
- Jianbo An,
- Akari Saku,
- Ryota Nukiwa,
- Daichi Utsumi,
- Maki Kiso,
- Atsuhiro Yasuhara,
- Vincent Kwok-Man Poon,
- Chris Chung-Sing Chan,
- Yuji Fujino,
- Satoru Motoyama,
- Satoshi Nagata,
- Josef M. Penninger,
- Haruhiko Kamada,
- Kwok-Yung Yuen,
- Wataru Kamitani,
- Ken Maeda,
- Yoshihiro Kawaoka,
- Yasuhiro Yasutomi,
- Yumiko Imai,
- Keiji Kuba
Affiliations
- Tomokazu Yamaguchi
- Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine
- Midori Hoshizaki
- Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine
- Takafumi Minato
- Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine
- Satoru Nirasawa
- Biological Resources and Post-Harvest Division, Japan International Research Center for Agricultural Sciences
- Masamitsu N. Asaka
- Tsukuba Primate Research Center, NIBIOHN
- Mayumi Niiyama
- Laboratory of Biopharmaceutical Research, NIBIOHN
- Masaki Imai
- Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo
- Akihiko Uda
- Department of Veterinary Science, National Institute of Infectious Diseases
- Jasper Fuk-Woo Chan
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Saori Takahashi
- Akita Research Institute of Food and Brewing
- Jianbo An
- Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine
- Akari Saku
- Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine
- Ryota Nukiwa
- Laboratory of Regulation of Intractable Infectious Diseases, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN)
- Daichi Utsumi
- Tsukuba Primate Research Center, NIBIOHN
- Maki Kiso
- Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo
- Atsuhiro Yasuhara
- Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo
- Vincent Kwok-Man Poon
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Chris Chung-Sing Chan
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Yuji Fujino
- Department of Anesthesiology and Intensive Care Medicine, Osaka University Graduate School of Medicine
- Satoru Motoyama
- Department of Surgery, Akita University Graduate School of Medicine
- Satoshi Nagata
- Laboratory of Antibody Design, NIBIOHN
- Josef M. Penninger
- Department of Medical Genetics, Life Sciences Institute, University of British Columbia
- Haruhiko Kamada
- Laboratory of Biopharmaceutical Research, NIBIOHN
- Kwok-Yung Yuen
- State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- Wataru Kamitani
- Department of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University
- Ken Maeda
- Department of Veterinary Science, National Institute of Infectious Diseases
- Yoshihiro Kawaoka
- Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo
- Yasuhiro Yasutomi
- Tsukuba Primate Research Center, NIBIOHN
- Yumiko Imai
- Laboratory of Regulation of Intractable Infectious Diseases, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN)
- Keiji Kuba
- Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine
- DOI
- https://doi.org/10.1038/s41467-021-27097-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Endogenous ACE2 is a receptor for SARS-CoV-2 and a recombinant soluble ACE2 protein can inhibit SARS-CoV-2 infection acting as a decoy. Here the authors show that B38-CAP, an ACE2-like enzyme but not a decoy for the virus, is protective against SARS-CoV-2-induced lung injury in animal models.
